Limited Distribution Drug Access for Infusion Providers
U.S. infusion sales hit $39.9 billion in 2025, up from $32.8 billion the year before. Roughly 11% compound annual growth over the preceding five years. The market is not slowing, and the drug pipeline feeding it keeps getting more complex.
The breakdown matters more than the headline number. Acute therapy accounts for $24.6 billion of that 2025 figure; chronic therapy accounts for $15.4 billion. Chronic therapies carry a disproportionate share of limited distribution drugs because they require ongoing supply chains, continuous patient monitoring, and the kind of manufacturer visibility into patient populations that open distribution cannot provide. You cannot just open the tap and let the drug flow wherever it goes.
The pipeline reinforces the trajectory. Since 2016, 137 novel infused drugs have received approval, with nearly 400 more in development and over 550 already operating in the home infusion setting. Nearly half of all FDA new molecular entity approvals since January 2021 require injection. The home infusion market specifically sat at $19.56 billion in 2025 and is projected to reach $39.57 billion by 2035. The National Home Infusion Association estimates roughly 3.2 million patients served annually by nearly 1,000 pharmacy-based providers.
More drugs entering the market will arrive as limited distribution drugs. The manufacturers designing those programs are making deliberate choices about who gets access, and an infusion provider who has not built the underlying infrastructure is watching a market move away from them. The market itself is moving, and the gap is growing.
How drugs actually move from manufacturer to infusion site
Most providers understand the surface-level logic: drug goes from manufacturer to distributor to pharmacy to patient. The limited distribution reality is considerably more intricate than that, and the intricacy is precisely where access gets determined.
Authorized distributors, companies like McKesson, Cardinal Health, and CuraScript SD, receive product from manufacturers and move it downstream. "Authorized" does not mean "unrestricted." The authorization can be narrow, conditional, and site-specific, and it frequently is.
In practice, infusion providers encounter three distinct distribution models. The first is direct-to-infusion-site: a limited network of home infusion specialty pharmacy providers delivers directly to patients, while a separate specialty distributor serves hospitals and hospital outpatient departments. The second is specialty pharmacy as hospital intermediary, where third-party logistics providers and a limited specialty pharmacy network deliver to hospitals for administration. ELEVIDYS follows this structure and is a documented example of how manufacturers construct these pipelines with real precision. The third is a hub-and-spoke hybrid, where a central specialty pharmacy supplies local infusion centers. Payers and health systems are actively experimenting with this model to extend reach without multiplying the number of credentialed sites they need to maintain.
The 2024 partnership between GC Biopharma and AOM Infusion for ALYGLO illustrates a broader pattern: manufacturers actively select infusion-specific partners when building limited distribution networks. They are not simply designating any qualified specialty pharmacy. They are choosing partners whose infrastructure, clinical quality, and data capabilities align with how they want the product managed, because for these products, how the drug is managed is inseparable from what the drug does.
What determines which model applies to any given drug: the drug's clinical profile, any REMS requirements, storage and handling needs, and the manufacturer's strategic goals around data visibility and network control. An infusion provider operating across a diverse drug portfolio will need to navigate all three models simultaneously. The discipline is understanding which model a specific drug uses before pursuing any relationship or credentialing conversation. Starting that conversation without that knowledge signals to the manufacturer that you are not ready.
Where independent infusion providers get squeezed out of these networks
The pressure on independent infusion providers is structural, not incidental, and it has intensified measurably over the past decade.
PBM-affiliated pharmacies received 68% of specialty drug dispensing revenue in 2023, up from 54% in 2016, per the FTC's January 2025 report. That shift did not happen organically. It happened because the four dominant specialty pharmacy networks, CVS Health, Express Scripts' Accredo, Alliance Rx Walgreens, and Optum Specialty Pharmacy, hold advantages embedded in the architecture of how benefit design works. PBM-owned pharmacies can be favored in formulary positioning, steering patient volume internally before an independent provider ever enters the picture. Express Scripts and Prime Therapeutics have used preferred biosimilar programs to route volume through affiliated pharmacies. Optum combines infusion operations, including over 60 sites, more than 800 home infusion nurses, and access to roughly 4,800 medications, with PBM and care management infrastructure that independent operators cannot replicate at scale. That is not a criticism; it is just the reality of what you are competing against.
There is a counterweight worth understanding, though. Per 2025 Drug Channels analysis, PBM-affiliated pharmacies have access to only one-quarter of exclusive-network products. The most restricted limited distribution drugs, the ones with the highest margins and the greatest clinical complexity, are disproportionately going to independent specialty pharmacies. Manufacturers of those products prefer independents for clinical quality and data transparency reasons. Being small and specialized is not a handicap in that corner of the market. It is often the whole point.
The FTC interim reports have documented active patient steerage toward PBM-owned pharmacies, with direct consequences for referral flow. Volume that should reach independent providers gets diverted instead. Beyond market structure, there is a workflow burden that compounds the problem. For limited distribution drugs, clinicians often must call the pharmacy multiple times just to confirm shipment dates. When providers lack visibility into when a patient is starting therapy, the operational friction falls hardest on those without integrated hub infrastructure to absorb that coordination cost.
Geographic inequity layers on top of all of this. Only large, well-resourced infusion centers can absorb the execution uncertainty that complex drug delivery requires: standby clinical teams, reserved capacity, cryogenic handling protocols. Rural and smaller independent providers face a structural disadvantage that credentialing alone cannot remedy. Credentialing is necessary. It is not sufficient, and anyone who tells you otherwise is selling something.
Accreditation as the practical entry point for LDD network designation
Pharmaceutical manufacturers designate specialty pharmacies for limited distribution networks, and they frequently require accreditation as a condition of that designation. This is not an abstract quality signal. It is a gate. The drugs behind that gate carry the highest specialty drug margins in the market, which means the credential directly protects revenue.
The two primary credentialing bodies cover distinct but overlapping ground. URAC Specialty Pharmacy Accreditation is a three-year credential; the current standard is v6.0, announced in October 2025, succeeding v5.0 which had been active since October 2022. It covers nine operational modules: patient management, medication distribution, cold-chain integrity, clinical safety, consumer protection, staff qualifications, quality improvement, performance measurement, and reporting. ACHC is the principal alternative. ACHC Infusion Pharmacy Standards were updated June 1, 2024, to incorporate revised USP Chapter 797 sterile compounding standards. Infusion pharmacies handling hazardous drugs must add separate Hazardous Drug Handling accreditation under USP Chapter 800.
Network-specific requirements are non-negotiable and must be tracked explicitly. OptumRx contractually requires URAC, ACHC, or TJC accreditation for specialty pharmacy network participation. CVS Caremark and Express Scripts maintain comparable credentialing requirements for specialty pharmacy and limited distribution network inclusion.
Dual accreditation is becoming the practical standard. Manufacturers are increasingly requiring multiple validations, and a provider holding only one credential will be ineligible for certain limited distribution designations even when their clinical operations are genuinely strong. I have seen good operators miss the window simply because they assumed one credential was enough.
Accreditation selection is not purely a quality decision. It is a strategic one. Which credential to pursue first, or whether to pursue both simultaneously, should be driven by which manufacturer relationships and payer networks are the actual target. Map the manufacturer's requirements before investing in the credentialing process, not afterward when you discover you chose the wrong one.
REMS programs and what compliance actually requires at the infusion site
A Risk Evaluation and Mitigation Strategy is not a single standard. It is a drug-specific program whose requirements depend entirely on each product's particular safety profile. One REMS might require only a patient registry. Another might require prescriber certification, site certification, defined monitoring periods, and specific antidote stocking. There is no universal checklist; there is only the specific program for the specific drug.
What REMS compliance actually demands of an infusion site is documentation and reporting infrastructure capable of satisfying program-specific requirements on an ongoing basis. Specialty pharmacies built advanced information systems specifically for this. Infusion providers seeking limited distribution designation need comparable capabilities, because the manufacturer's visibility into compliance is continuous. You are not checked once and left alone. The reporting never stops.
For CAR-T cell therapies specifically, REMS had historically required site certification, tocilizumab stocking, and defined post-infusion proximity periods that concentrated eligible administration sites at large academic medical centers. On June 27, 2025, FDA removed REMS requirements for all approved BCMA- and CD19-directed autologous CAR-T cell therapies, citing that product labeling now sufficiently communicates safety information. That removal eliminated the site certification requirement and the tocilizumab stocking requirement, reduced the recommended post-infusion proximity period from four weeks to two weeks, and introduced increased flexibility on monitoring locations. Prior REMS requirements had delayed CAR-T access for rural and underserved patients by concentrating eligible sites geographically. The June 2025 change opens the door for more infusion providers to qualify.
What the change does not resolve matters equally. REMS removal for CAR-T does not affect the handling complexity, chain-of-custody requirements, or infrastructure demands that still determine which sites can realistically administer these therapies. A provider newly eligible under the revised regulatory framework still needs the underlying operational infrastructure. The credential and the capability are entirely different things, and conflating them is a mistake that will cost you time and relationships.
Cell and gene therapies as the hardest case of LDD access
FDA approved five gene therapy products in both 2024 and 2025. Approximately 2,000 active gene therapy products are in clinical trials, with nearly half cell-based. The infusion pipeline will increasingly include these products, and the access challenges they present are categorically different from any other limited distribution drug.
The distribution complexity starts at manufacturing. Cells are collected from the patient, transported under ultra-low temperature conditions to a manufacturing facility for genetic modification, then shipped back to the treatment site. Each step is irreversible and time-critical. Any break in the chain-of-identity or chain-of-custody is not a documentation problem; it is a patient safety event. Specialized cryogenic couriers handle transport because standard pharmaceutical distributors are not equipped for it. Coordination at the treatment center involves manufacturing schedules, planning teams, and therapy-specific portals that require dedicated personnel and purpose-built workflows. This is less like filling a prescription and more like conducting an orchestrated handoff where everyone has to be in position before the previous party lets go, and there is no pausing the music if someone is late.
The structural bottleneck from 2024 to 2025 was not regulatory. The number of qualified cell and gene therapy centers in the U.S. did not increase meaningfully during that period. The barrier was site capacity: the ability to reserve ICU beds, maintain standby clinical teams, and absorb the operational and financial risk of delayed or failed delivery. These are not incremental investments.
For an infusion provider considering cell and gene therapy access, qualification is primarily an infrastructure investment decision, not a credentialing exercise. Most independent and smaller infusion providers cannot make those investments incrementally, and the geographic concentration of qualified sites that results forces patients in rural and underserved areas to travel significant distances for treatment. The June 2025 REMS changes for CAR-T partially address this by removing formal site certification barriers, but the underlying infrastructure requirements remain. Regulatory relief and operational readiness are not interchangeable, and the distance between them is where access actually breaks down.
The legislative and regulatory environment shaping LDD access through 2026
The FTC launched sweeping PBM investigations in mid-2022. The interim reports that followed documented both the revenue concentration shift to PBM-affiliated pharmacies and the steerage practices disadvantaging independent operators. The $7.3 billion the Big 3 PBMs generated from marking up specialty generics between 2017 and 2022 is a number the FTC published explicitly. It signals something precise: formulary control is not just a patient-steering mechanism. It is a margin extraction mechanism, and it is now under formal federal scrutiny.
The Drug Channels 2025 finding that PBM-affiliated pharmacies access only one-quarter of exclusive-network products points to a counterforce already operating in the market. Manufacturers are using limited distribution network design to limit PBM leverage, routing the most restricted and highest-margin products to independent specialty pharmacies that can demonstrate clinical quality and data capabilities. That is happening now.
Ongoing PBM policy and legislative activity through late 2025 continues to target steerage practices and vertical integration. The direction of travel favors broader independent access. Implementation timelines remain uncertain, and the gap between legislative intent and operational reality has historically been considerable in this market. Anyone who has watched prior rounds of PBM reform knows that the distance between a passed bill and a changed patient experience can span years.
Regulatory and legislative pressure is building against the gatekeeping structures that currently disadvantage independent infusion providers. But that pressure creates opportunity only for providers who have already built the infrastructure: the accreditation, the compliance systems, the manufacturer relationships, the clinical documentation capabilities. Policy change opens doors. It does not build the rooms behind them. The providers who benefit from a more open regulatory environment will be the ones who prepared for it before the environment changed.
